KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EBITDA (2016 - 2025)

Sarepta Therapeutics has reported EBITDA over the past 15 years, most recently at -$411.6 million for Q4 2025.

  • Quarterly results put EBITDA at -$411.6 million for Q4 2025, down 354.56% from a year ago — trailing twelve months through Dec 2025 was -$694.8 million (down 390.49% YoY), and the annual figure for FY2025 was -$699.8 million, down 420.88%.
  • EBITDA for Q4 2025 was -$411.6 million at Sarepta Therapeutics, down from -$179.7 million in the prior quarter.
  • Over the last five years, EBITDA for SRPT hit a ceiling of $196.8 million in Q2 2025 and a floor of -$515.5 million in Q1 2023.
  • Median EBITDA over the past 5 years was -$93.4 million (2021), compared with a mean of -$105.6 million.
  • Peak annual rise in EBITDA hit 3115.28% in 2025, while the deepest fall reached 970.43% in 2025.
  • Sarepta Therapeutics' EBITDA stood at -$122.0 million in 2021, then grew by 11.71% to -$107.7 million in 2022, then surged by 143.83% to $47.2 million in 2023, then soared by 242.46% to $161.7 million in 2024, then crashed by 354.56% to -$411.6 million in 2025.
  • The last three reported values for EBITDA were -$411.6 million (Q4 2025), -$179.7 million (Q3 2025), and $196.8 million (Q2 2025) per Business Quant data.